The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Menée in vitro et à l'aide de xénogreffes de tumeurs issues de patients, cette étude met en évidence le potentiel de la protéine Schlafen11 pour prédire l'efficacité des agents endommageant l'ADN ou inhibant la réponse aux dommages causés à l'ADN
The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.
British Journal of Cancer , éditorial en libre accès, 2020